Fei Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Fei Chen has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Jian-Guo Chen
Department of Epidemiology, Qidong Liver Cancer Institute, Qidong People’s Hospital, Affiliated Qidong Hospital of Nantong University, Qidong 226200, China
1 shared publication - Kevin Beezhold
Laboratory of Cancer Signaling and Epigenetics, Health Effects Laboratory Division, Pathology and Physiology Research Branch, National Institute for Occupational Safety and Health, 1095 Willowdale Road, Morgantown, WV 26505, USA
1 shared publication - Qingshan Chang
Graduate Center for Toxicology, University of Kentucky, Lexington, KY40536, USA
1 shared publication Vince Castranova
The Health Effects Laboratory Division, National Institute for Occupational Safety and Health, Morgantown, West Virginia
1 shared publication- Vincent Castranova
Pathology and Physiology Research Branch, HELD, NIOSH, Morgantown, WV, USA
1 shared publication - Xianglin Shi
Center for Research on Environmental Disease, University of Kentucky, Lexington, KY, USA
1 shared publication
Latest Publications
- Open Access
- 17 August 2009
- Published by Springer Nature in Molecular Cancer
- Vol. 8 (1) , 64
JNK1 activation predicts the prognostic outcome of the human hepatocellular carcinoma
Background: Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide with an extremely poor prognosis. The classification of HCC based on the molecular signature is not well-established. Results: In the present study, we reported HCC signature genes based on the JNK1 activation status in 31 HCC specimens relative to the matched distal noncancerous liver tissue from 31 patients. The HCCs with high JNK1 (H-JNK1) and low JNK1 (L-JNK1) were sub-grouped. Two different signature gene sets for both H-JNK1 and L-JNK1 HCC were identified through gene expression profiling. A striking overlap of signature genes was observed between the H-JNK1 HCC and the hepatoblastoma or hepatoblastoma-type HCC. Many established biomarkers for hepatic progenitor cells were over-expressed in H-JNK1 HCC, including AFP, TACSTD1, KRT19, KRT7, THY1, and PROM1. In addition, the majority of the most up-regulated genes were those associated with metastasis and earlier recurrence, whereas the genes for normal liver function were substantially down-regulated in H-JNK1 HCC tissue. A Kaplan-Meier plot demonstrated that the survival of the patients with H-JNK1 HCC was severely impaired. Conclusion: Accordingly, we believe that the H-JNK1 HCC may originate from hepatic progenitor cells and is associated with poorer prognosis. The status of JNK1 activation in HCC tissue, thus, might be a new biomarker for HCC prognosis and therapeutic targeting.
- 17 August 2009
- Published by Springer Nature in Molecular Cancer
- Vol. 8 (1) , 64
Open AccessJNK1 activation predicts the prognostic outcome of the human hepatocellular carcinoma
Background: Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide with an extremely poor prognosis. The classification of HCC based on the molecular signature is not well-established. Results: In the present study, we reported HCC signature genes based on the JNK1 activation status in 31 HCC specimens relative to the matched distal noncancerous liver tissue from 31 patients. The HCCs with high JNK1 (H-JNK1) and low JNK1 (L-JNK1) were sub-grouped. Two different signature gene sets for both H-JNK1 and L-JNK1 HCC were identified through gene expression profiling. A striking overlap of signature genes was observed between the H-JNK1 HCC and the hepatoblastoma or hepatoblastoma-type HCC. Many established biomarkers for hepatic progenitor cells were over-expressed in H-JNK1 HCC, including AFP, TACSTD1, KRT19, KRT7, THY1, and PROM1. In addition, the majority of the most up-regulated genes were those associated with metastasis and earlier recurrence, whereas the genes for normal liver function were substantially down-regulated in H-JNK1 HCC tissue. A Kaplan-Meier plot demonstrated that the survival of the patients with H-JNK1 HCC was severely impaired. Conclusion: Accordingly, we believe that the H-JNK1 HCC may originate from hepatic progenitor cells and is associated with poorer prognosis. The status of JNK1 activation in HCC tissue, thus, might be a new biomarker for HCC prognosis and therapeutic targeting.
- 1 December 2007
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 67 (23) , 11093-11098
Nuclear Factor-κB, an Unappreciated Tumor Suppressor
The notion that nuclear factor-κB (NF-κB) is a tumor-promoting transcription factor has become a widely accepted dogma in biology. However, recent findings suggest an inhibitory role for NF-κB in carcinogenesis and tumorigenesis. Although the tumor suppressor–like effect of NF-κB remains to be rigorously established by further studies using cellular and animal models, these latest findings warrant caution with respect to blockage of NF-κB activation as a broad strategy in treating cancers. [Cancer Res 2007;67(23):11093–8]
- 1 December 2007
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 67 (23) , 11093-11098
Nuclear Factor-κB, an Unappreciated Tumor Suppressor
The notion that nuclear factor-κB (NF-κB) is a tumor-promoting transcription factor has become a widely accepted dogma in biology. However, recent findings suggest an inhibitory role for NF-κB in carcinogenesis and tumorigenesis. Although the tumor suppressor–like effect of NF-κB remains to be rigorously established by further studies using cellular and animal models, these latest findings warrant caution with respect to blockage of NF-κB activation as a broad strategy in treating cancers. [Cancer Res 2007;67(23):11093–8]
- 1 June 2005
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 332 (1) , 1-3
Is NF-κB a culprit in type 2 diabetes?
- 1 June 2005
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 332 (1) , 1-3
Is NF-κB a culprit in type 2 diabetes?